Study Phase 2

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Trial Information

Generic NameSelexipagProduct NameUPTRAVI®Therapeutic AreaBlood and Blood-Forming OrgansProduct ClassAntithrombotic AgentsPharmacological SubgroupAntithrombotic AgentsChemical SubgroupPlatelet Aggregation Inhibitors, excluding HeparinCondition StudiedScleroderma, Systemic
Sponsor Protocol NumberAC-065C202Enrollment74Data PartnerJohnson & Johnson% Female81.1%Mean/Median Age (Years)52.6% White93.2%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.